Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease

Arnott, I. D. R., McNeill, G., Satsangi, J. · 2003 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: 59–81% of patients given infliximab for Crohn's disease will respond. Although now in widespread use, little consensus exists regarding the optimal place in patient care. Recently developed guidelines have identified need for markers that predict response. Aims: We aimed to identify markers of response to infliximab given for Crohn's disease. Methods: Markers of response (defined at 4 weeks) were prospectively assessed in 74 infliximab‐treated patients with Crohn's disease. Patients were followed‐up to 1 year. Results: Fifty‐four of 74 (73%) patients responded. Univariate analysis identified that smokers were less likely to respond than non‐smokers [P = 0.005, odds ratio (OR) 0.22]. Patients established on immunosuppression (P = 0.034, OR 7.31) and with isolated colonic disease (P = 0.042, OR 3.83) were more likely to respond. Multiple logistic regression confirmed smoking (P = 0.035, OR 0.24) and colonic disease (P = 0.035, OR 4.87) as independent markers of response. One‐year relapse rates differed significantly between smokers and non‐smokers (100% vs. 39.6%, P = 0.0026, relative risk 3.2) and between patients established on immunomodulators or not (58.0% vs. 92.8%, P = 0.0054, relative risk 2.6). Conclusions: Smoking has a strong adverse effect on the response rates and maintenance of response to infliximab. Patients on immunomodulators have a more favourable short‐ and long‐term response. These results have important implications for clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2003.01574.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 192

Metadata

Authors
Arnott, I. D. R., McNeill, G., & Satsangi, J.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2003-06
Volume
17
Issue
12
Pages
1451-1457
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2090638706
Cited by
192
References
1
FWCI
5.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease. https://app.cochat.ai/papers/10.1046/j.1365-2036.2003.01574.x
The paper
Arnott, I. D. R., McNeill, G., & Satsangi, J. (2003). An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2003.01574.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.